Subscribe to NRx Newsletter
Read the latest news about our company, medicines, and pipeline below.

Recent News & Articles

NRx Press Release

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

NRx Pharmaceuticals today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs.  She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.  

NRx Press Release

NRx Receives Nasdaq Notice of Listing Compliance

NRx Pharmaceuticals today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the Company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.

NRx Press Archives

Analyst Coverage

Ascendiant Capital Markets LLC – Member FINRA & SIPC
Edward Woo, CFA
Senior Research Analyst, D.O.R.

H.C. Wainwright & Co., LLC
Vernon Bernadino
Managing Director


  To Be Announced

Past Events

41st Annual J.P. Morgan Health Care Conference
January 9-12, 2023
Westin St. Francis Hotel
San Francisco, CA

6th Annual Sachs Associates Neuroscience Innovation Forum
Click here for Video Presentation

January 8, 2023
Ritz Carlton Hotel
San Francisco, CA

Cantor Neurology & Psychiatry Conference
October 6-7, 2022
Ritz Carlton Hotel
San Francisco, CA

HC Wainwright 24th Annual Global Investment Conference
September 12-14, 2022
Lotte New York Palace Hotel
New York, NY